Anne-Marie Thielen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Marie Thielen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
C. Barde
3 shared publicationsJ.-H. Saurat
2 shared publicationsJ.H. Saurat
Department of Dermatology, University Hospital Geneva, Geneva, Switzerland
2 shared publicationsL. Borradori
2 shared publications- Emmanuel Laffitte
Clinique de Dermatologie, Hôpitaux Universitaires de Genève, Rue Gabrielle Perret-Gentil 4, CH-1211, Genève, Switzerland.
1 shared publication G. Marazza
1 shared publication
Latest Publications
- 22 April 2009
- Vol. 5 (200) , 876, 878-81
[Topical treatments for psoriasis in 2009].
Psoriasis is a chronic inflammatory disease causing important physical and psychological morbidity. Topical treatments are the first choice therapeutic alternatives for mild and moderate psoriasis. We review the different topical treatment options for this common skin disease.
- 22 April 2009
- Vol. 5 (200) , 876, 878-81
[Topical treatments for psoriasis in 2009].
Psoriasis is a chronic inflammatory disease causing important physical and psychological morbidity. Topical treatments are the first choice therapeutic alternatives for mild and moderate psoriasis. We review the different topical treatment options for this common skin disease.
- 26 May 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (2) , 137-139
Long-Term Control with Etanercept (Enbrel®) of a Severe Acrodermatitis Continua of Hallopeau Refractory to Infliximab (Remicade®)
Hallopeau’s acrodermatitis is characterized by the presence of aseptic pustules on an inflammatory basis of the periungual or subungual region. The cyclic recurrences induce important physical and psychological morbidity. By analogy to the efficacy of TNF-α antagonists in the treatment of generalized pustular psoriasis, our patient illustrates the long-term efficacy and safety of etanercept (Enbrel®) in the treatment of Hallopeau’s acrodermatitis refractory to infliximab (Remicade®). This treatment alternative should in consequence be considered in patients with a recalcitrant form of a potentially debilitating disease.
- 26 May 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (2) , 137-139
Long-Term Control with Etanercept (Enbrel®) of a Severe Acrodermatitis Continua of Hallopeau Refractory to Infliximab (Remicade®)
Hallopeau’s acrodermatitis is characterized by the presence of aseptic pustules on an inflammatory basis of the periungual or subungual region. The cyclic recurrences induce important physical and psychological morbidity. By analogy to the efficacy of TNF-α antagonists in the treatment of generalized pustular psoriasis, our patient illustrates the long-term efficacy and safety of etanercept (Enbrel®) in the treatment of Hallopeau’s acrodermatitis refractory to infliximab (Remicade®). This treatment alternative should in consequence be considered in patients with a recalcitrant form of a potentially debilitating disease.
- 27 March 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (1) , 45-47
Chronic Hemicorporal Prurigo Related to a Posttraumatic Brown-Séquard Syndrome
Focal pruritus may have a neurological cause. According to the underlying mechanism, two categories of central itch have been distinguished, neuropathic and neurogenic pruritus. We here describe a patient with Brown-Séquard syndrome related to unilateral damage of the spinal cord. The patient progressively developed neuropathic pruritus with chronic prurigo lesions showing strictly hemicorporal distribution. The patient was given pregabalin, an analogue of the neurotransmitter γ-aminobutyric acid,with significant improvement. Our observation of chronic prurigo with hemicorporal involvement is unique. It underscores the importance of a detailed neurological examination in case of persistent localized itch and further supports the idea that chronic prurigo reflects a neurological problem in a subset of affected patients. Antiepileptic drugs should be considered not only for neuropathic pain, but also for neuropathic itch.
- 27 March 2008
- Published by S. Karger AG in Dermatology
- Vol. 217 (1) , 45-47
Chronic Hemicorporal Prurigo Related to a Posttraumatic Brown-Séquard Syndrome
Focal pruritus may have a neurological cause. According to the underlying mechanism, two categories of central itch have been distinguished, neuropathic and neurogenic pruritus. We here describe a patient with Brown-Séquard syndrome related to unilateral damage of the spinal cord. The patient progressively developed neuropathic pruritus with chronic prurigo lesions showing strictly hemicorporal distribution. The patient was given pregabalin, an analogue of the neurotransmitter γ-aminobutyric acid,with significant improvement. Our observation of chronic prurigo with hemicorporal involvement is unique. It underscores the importance of a detailed neurological examination in case of persistent localized itch and further supports the idea that chronic prurigo reflects a neurological problem in a subset of affected patients. Antiepileptic drugs should be considered not only for neuropathic pain, but also for neuropathic itch.
- 10 November 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (1) , 188-189
Reiter syndrome triggered by adalimumab (Humira�) and leflunomide (Arava�) in a patient with ankylosing spondylarthropathy and Crohn disease
- 10 November 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (1) , 188-189
Reiter syndrome triggered by adalimumab (Humira�) and leflunomide (Arava�) in a patient with ankylosing spondylarthropathy and Crohn disease
- 31 July 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (4) , 846-847
Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva® )
- 31 July 2006
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (4) , 846-847
Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva® )
- 1 October 2005
- Published by S. Karger AG in Dermatology
- Vol. 211 (3) , 209-217
Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature
The use of biological agents is expanding worldwide as a new treatment alternative for chronic inflammatory diseases including more recently skin diseases, especially psoriasis. Although frequently observed, the knowledge about acute and chronic dermatological adverse events is limited, and potential pathogenic mechanisms still have to be identified. Exact diagnosis is required considering that dermatological adverse events raise a decisional challenge about potential treatment discontinuation. The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives.
- 1 October 2005
- Published by S. Karger AG in Dermatology
- Vol. 211 (3) , 209-217
Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature
The use of biological agents is expanding worldwide as a new treatment alternative for chronic inflammatory diseases including more recently skin diseases, especially psoriasis. Although frequently observed, the knowledge about acute and chronic dermatological adverse events is limited, and potential pathogenic mechanisms still have to be identified. Exact diagnosis is required considering that dermatological adverse events raise a decisional challenge about potential treatment discontinuation. The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives.